Comparing the current results to its competitors, Immunocore Holdings Plc reported Revenue increase in the 2 quarter 2026 by 18.34 % year on year. The revenue growth was below Immunocore Holdings Plc's competitors' average revenue growth of 34.4 %, achieved in the same quarter.
Immunocore Holdings Plc's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancements and intense competition. It considers its approach, strategy, TCR experience, and ImmTAX platform as competitive factors. The company faces substantial competition from major pharmaceutical and specialty pharmaceutical firms, established and emerging biotechnology companies, as well as academic, governmental, and private research institutions globally. Competitors often possess greater financial, technical, and other resources, along with expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also present competition, particularly through collaborations with larger entities. Additional competitive challenges include recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. Specifically, the company competes with entities developing TCR-based therapeutics for cancer, including Adaptimmune Therapeutics plc and Immatics Biotechnologies. Deutsche Post DHL Group is also noted among competitors in filings.
November 7, 2025
Immunocore Presents Phase 1 Data for Hepatitis B Candidate at AASLD s The Liver Meeting In an era marked by remarkable advances in therapeutic strategies, Immunocore has taken a significant step forward in the battle against hepatitis B. At the prestigious American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held recently, the biopharmaceutical company unveiled compelling Phase 1 clinical trial data for its promising investigational drug, IMC-I109V. This candidate has generated considerable excitement within the scientific community, primarily owing to its encouraging safety profile and demonstrable antiviral effectiveness.The Phase 1 clinical trial was designed to evaluate the saf...
December 17, 2024
In the fast-paced world of biopharmaceutical innovation, Immunocore Holdings Plc continues to forge ahead with promising research endeavors, despite facing formidable competition on multiple fronts. A notable development for the company involves the recent announcement of initiating the Phase 1/2 trial of IMC-R117C a novel therapeutic candidate targeting the PIWIL1 protein in advanced gastrointestinal cancers. IMC-R117C: Pioneering New Therapeutic AvenuesImmunocore s cutting-edge bispecific T-cell receptor technology underpins the development of IMC-R117C. The drug is designed to recognize the PIWIL1 protein expressed in various advanced cancers, providing a targeted treatment approach. This advanced-stage ...
December 3, 2024
Immunocore Holdings Plc (NASDAQ: IMCR) has announced a significant milestone in cancer treatment as it has finalized a reimbursement agreement in England for its innovative therapy, KIMMTRAK, aimed at HLA-A 02:01-positive adults suffering from unresectable or metastatic uveal melanoma. This landmark decision is expected to enhance patient access to a vital therapy that has shown promising results in treating this rare form of cancer.Uveal melanoma, an aggressive cancer that arises from the uvea of the eye, poses treatment challenges due to its metastatic potential. For those adults who test positive for the HLA-A 02:01 antigen, KIMMTRAK offers a new ray of hope, leveraging the power of T-cell engagement to t...
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients' lives.
Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.
Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.
Sources:
Immunocore Holdings Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immunocore Holdings Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
